Jerome Alexandre
Overview
Explore the profile of Jerome Alexandre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
149
Citations
4137
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Gernier F, Ahmed-Lecheheb D, Pautier P, Floquet A, Nadeau C, Frank S, et al.
BMC Cancer
. 2021 Oct;
21(1):1147.
PMID: 34702204
Background: Germ cell tumors and sex cord stromal tumors are rare cancers of the ovary. They mainly affect young women and are associated with a high survival rate. The standard...
32.
Boudou-Rouquette P, Arrondeau J, Gervais C, Durand J, Fabre E, De Percin S, et al.
EBioMedicine
. 2021 Oct;
73:103630.
PMID: 34688030
Background: Immune checkpoint inhibitors (ICI) are dramatically active in a minority of non-small cell lung cancer (NSCLC) patients. We studied here the relationship between patients's metabolism and outcome under ICI....
33.
Berton D, Floquet A, Lescaut W, Baron G, Kaminsky M, Toussaint P, et al.
Front Pharmacol
. 2021 Oct;
12:711813.
PMID: 34616296
Bevacizumab-containing therapy is considered a standard-of-care front-line option for stage IIIB-IV ovarian cancer based on results of randomized phase 3 trials. The multicenter non-interventional ENCOURAGE prospective cohort study assessed treatment...
34.
OMalley D, Oaknin A, Monk B, Selle F, Rojas C, Gladieff L, et al.
Gynecol Oncol
. 2021 Aug;
163(2):274-280.
PMID: 34452745
Objective: This phase II clinical trial evaluated the safety and antitumor activity of balstilimab, an anti-PD-1 antibody, in patients with previously-treated, recurrent/metastatic cervical cancer. Methods: Eligible patients were 18 years...
35.
Velev M, Puszkiel A, Blanchet B, De Percin S, Delanoy N, Medioni J, et al.
Pharmaceuticals (Basel)
. 2021 Aug;
14(8).
PMID: 34451901
Factors associated with olaparib toxicity remain unknown in ovarian cancer patients. The large inter-individual variability in olaparib pharmacokinetics could contribute to the onset of early significant adverse events (SAE). We...
36.
Tlemsani C, Arrondeau J, De Percin S, Gataa I, Bretagne M, Ajgal Z, et al.
Clin Med (Lond)
. 2021 Aug;
21(5):e552-e555.
PMID: 34341004
Cancer patients are a highly vulnerable group in the COVID-19 pandemic and it has been necessary for oncology units to adapt to this unexpected situation. We present our management of...
37.
Bellesoeur A, Gataa I, Jouinot A, Mershati S, Piketty A, Tlemsani C, et al.
Cancer Chemother Pharmacol
. 2021 Jul;
88(4):741-751.
PMID: 34304283
Background: The risk of drug-drug interactions (DDI) has become a major issue in cancer patients. However, data in sarcoma patients are scarce. We aimed to evaluate the frequency and the...
38.
Evrard C, Alexandre J
Cancers (Basel)
. 2021 Jun;
13(10).
PMID: 34069845
For endometrial cancer, a new classification is now available from ESMO, ESGO, and ESTRO based on clinical and molecular characteristics to determine adjuvant therapy. The contribution of molecular biology is...
39.
Kaneko Y, Hatano R, Hirota N, Isambert N, Trillet-Lenoir V, You B, et al.
Biomark Res
. 2021 Mar;
9(1):21.
PMID: 33757558
Background: The phase I trial of the humanized anti-CD26 monoclonal antibody YS110 for CD26-expressing tumors was conducted recently. The present study identifies a potential prognostic biomarker for CD26-targeted therapy based...
40.
Aide N, Fauchille P, Coquan E, Ferron G, Combe P, Meunier J, et al.
Eur J Nucl Med Mol Imaging
. 2020 Nov;
48(6):1998-2008.
PMID: 33221969
Background: This ancillary study aimed to evaluate F-FDG PET parameter changes after one cycle of treatment compared to baseline in patients receiving first-line neoadjuvant anti-angiogenic nintedanib combined to paclitaxel-carboplatin chemotherapy...